Raltegravir: the first HIV‐1 integrase strand transfer inhibitor in the HIV armamentarium
- 22 March 2011
- journal article
- research article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1222 (1) , 83-89
Abstract
Raltegravir is the first integrase strand transfer inhibitor approved for the treatment of HIV‐1 infection. As the first agent in this new class of antiretroviral therapies, raltegravir has demonstrated safety and efficacy in treatment‐naive as well as heavily pretreated HIV‐infected patients failing therapy with multidrug‐resistant virus. Raltegravir has a favorable drug interaction profile that permits both administration to a wide, demographically diverse patient population and coadministration with many other therapeutic agents, including antiretroviral agents and supportive medications, without restrictions or dose adjustment. Data through 96 weeks of follow‐up in three phase III studies, protocol 021 (STARTMRK) in treatment‐naive patients, and protocols 018 (BENCHMRK‐1) and 019 (BENCHMRK‐2) in treatment‐experienced patients, demonstrated the potent and durable antiretroviral and immunologic effects and the favorable long‐term safety profile of raltegravir in both treatment‐naive and treatment‐experienced patients. Raltegravir represents an important addition to the current armamentarium for the treatment of HIV infection.Keywords
This publication has 33 references indexed in Scilit:
- Retroviral intasome assembly and inhibition of DNA strand transferNature, 2010
- Effect of Tipranavir-Ritonavir on Pharmacokinetics of RaltegravirAntimicrobial Agents and Chemotherapy, 2009
- Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of RaltegravirAntimicrobial Agents and Chemotherapy, 2009
- Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir PharmacokineticsAntimicrobial Agents and Chemotherapy, 2009
- Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of RaltegravirAntimicrobial Agents and Chemotherapy, 2008
- Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2008
- Lack of a Significant Drug Interaction between Raltegravir and TenofovirAntimicrobial Agents and Chemotherapy, 2008
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionNew England Journal of Medicine, 2008
- Raltegravir with Optimized Background Therapy for Resistant HIV-1 InfectionNew England Journal of Medicine, 2008
- Lack of a Pharmacokinetic Effect of Raltegravir on Midazolam: In Vitro/In Vivo CorrelationThe Journal of Clinical Pharmacology, 2008